载有黄素的四面体框架核酸通过调节多个协同信号通路来缓解肺高血压
Xiaomeng Yue1, Jie Lan2, Lin Yang1
1Department of Radiology, Tianjin Medical University General Hospital, Tianjin, China.
Advanced healthcare materials
|January 14, 2026
概括
四面体框架核酸-库尔库 (tFNAs-Cur) 通过向多种疾病途径,为肺高血压 (PH) 提供了一种新的治疗方法. 这种创新疗法在改善PH症状和降低死亡率方面表现有前途.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 心血管研究研究心血管研究
背景情况:
- 肺高血压 (PH) 是一种严重的疾病,导致右心力衰竭.
- 目前的PH疗法难以解决氧化应激,炎症和细胞增殖等多种潜在机制,导致结果不佳.
- 对于能够同时调节这些核心病理途径的新型治疗方法有着至关重要的需求.
研究的目的:
- 开发和评估一种新的治疗剂,四面体框架核酸-库尔库 (tFNAs-Cur),用于治疗肺高血压 (PH).
- 研究tFNAs-Cur对关键PH通路的多目标协同治疗潜力,包括TGFβ1,NF-κB和PI3K-Akt.
- 评估tFNAs-Cur在细胞模型和PH的老鼠模型中的疗效和安全性.
主要方法:
- 合成和表征tFNAs-Cur,评估其药物负载,溶解性,稳定性和生物相容性.
- 使用肺动脉光滑肌细胞进行体外研究,以评估细胞吸收,氧化应激,增殖和迁移.
- 在体内研究中,使用单克罗他林诱导的PH大鼠模型来评估血液动力学,结构和功能上的改善.
- 转录和生化分析以阐明tFNAs-Cur.的潜在治疗机制.
主要成果:
- tFNAs-Cur显示了高的药物负载,良好的水溶性,稳定性和生物相容性.
- 细胞实验证实了肺动脉光滑肌细胞对tFNAs-Cur的有效内化,显著减少了氧化应激,增殖和迁移.
- 在PH大鼠模型中,tFNAs-Cur治疗改善了肺动脉加速时间,减少了血管壁厚度和中间直径,增强了运动能力,降低了富尔顿指数,并缓解了右心室纤维化.
- 机制研究表明,tFNAs-Cur通过调节ROS/TGFβ1抗氧化剂,NF-κB抗炎和PI3K-Akt抗增殖通路来发挥其治疗作用.
结论:
- tFNAs-Cur代表了肺高血压的新且有效的治疗策略.
- tFNAs-Cur的多目标方法同时解决了涉及PH病变发生的关键协同途径.
- tFNAs-Cur具有显著的临床转化潜力,因为其已证明的疗效,安全性和改善多个方面PH的能力.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
436
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
436
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
438
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
438
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
554
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
554
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
457
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
457
Pulmonary Hypertension: Classification and Pathogenesis
567
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
567
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K


